未找到相关数据
First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results
被引：17
作者：
Hamid, Omid
Thompson, John A.
Diab, Adi
Ros, Willeke
Eskens, Ferry
Bermingham, Candy
Konto, Cyril
Long, Hua
Liao, Ken
Ganguly, Bishu J.
Fleener, Catherine
Pleasic-Williams, Susan
Garzone, Pamela D.
Patel, Premal H.
Joh, Tenshang
Nuyten, Dimitry S. A.
El-Khoueiry, Anthony B.
机构：
[1] Angeles Clin & Res Inst, Los Angeles, CA USA
[2] Seattle Canc Care Alliance, Seattle, WA USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[4] Netherlands Canc Inst, Amsterdam, Netherlands
[5] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
[6] Rinat Pfizer, San Francisco, CA USA
[7] Pfizer, San Francisco, CA USA
[8] Pfizer, San Diego, CA USA
[9] Pfizer, Groton, CT USA
[10] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.3079
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3079
引用
收藏
页数：2
相关论文